How does altered compare with conventional whole brain radiotherapy in people with newly diagnosed multiple brain metastases?

2018 ◽  
Author(s):  
Sera Tort ◽  
Ivan Tham
Keyword(s):  
Brain Metastases ◽  
Whole Brain Radiotherapy ◽  
Newly Diagnosed ◽  
Whole Brain ◽  
Multiple Brain Metastases ◽  
Brain Radiotherapy

scholarly journals A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Carsten Nieder ◽  
Gro Aandahl ◽  
Astrid Dalhaug
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Metastatic Disease ◽  
Local Treatment ◽  
Whole Brain Radiotherapy ◽  
Maximum Size ◽  
Newly Diagnosed ◽  
Eribulin Mesylate ◽  
Whole Brain ◽  
Brain Radiotherapy

Patients with triple receptor-negative breast cancer often develop aggressive metastatic disease, which also might involve the brain. In many cases, systemic and local treatment is needed. It is important to consider the toxicity of chemo- and radiotherapy, especially when newly approved drugs become available. Randomised studies leading to drug approval often exclude patients with newly diagnosed brain metastases. Here we report our initial experience with eribulin mesylate and whole-brain radiotherapy (WBRT) in a heavily pretreated patient with multiple brain, lung, and bone metastases from triple receptor-negative breast cancer. Eribulin mesylate was given after 4 previous lines for metastatic disease. Two weeks after the initial dose, that is, during the first cycle, the patient was diagnosed with 5 brain metastases with a maximum size of approximately 4.5 cm. She continued chemotherapy and received concomitant WBRT with 10 fractions of 3 Gy. After 3 cycles of eribulin mesylate, treatment was discontinued because of newly diagnosed liver metastases and progression in the lungs. No unexpected acute toxicity was observed. The only relevant adverse reactions were haematological events after the third cycle (haemoglobin 9.5 g/dL, leukocytes3.1×109/L). The patient died from respiratory failure 18.5 months from diagnosis of metastatic disease, and 2.7 months from diagnosis of brain metastases. To the best of our knowledge, this is the first report on combined WBRT and eribulin mesylate.

scholarly journals Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases

2014 ◽  
Vol 106 (7) ◽  
Author(s):  
Siow Ming Lee ◽  
Conrad R. Lewanski ◽  
Nicholas Counsell ◽  
Christian Ottensmeier ◽  
Andrew Bates ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Randomized Trial ◽  
Whole Brain Radiotherapy ◽  
Whole Brain ◽  
Multiple Brain Metastases ◽  
Brain Radiotherapy ◽  
Nsclc Patients

Whole brain radiotherapy for the treatment of multiple brain metastases

2006 ◽  
Author(s):  
May N Tsao ◽  
Nancy Lloyd ◽  
Rebecca KS Wong ◽  
Edward Chow ◽  
Eileen Rakovitch ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Whole Brain Radiotherapy ◽  
Whole Brain ◽  
Multiple Brain Metastases ◽  
Brain Radiotherapy
Sign in / Sign up

Export Citation Format

Share Document